Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.59)
# 856
Out of 5,042 analysts
179
Total ratings
46.82%
Success rate
6.86%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $7.20 | +261.11% | 2 | Oct 15, 2025 | |
| ETNB 89bio | Downgrades: Market Perform | n/a | $14.79 | - | 11 | Sep 19, 2025 | |
| ATXS Astria Therapeutics | Reiterates: Overweight | $49 | $12.44 | +293.89% | 2 | Sep 17, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $32.92 | +91.37% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $38.09 | +285.93% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $70.02 | +17.11% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $7.13 | +40.25% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $22.99 | +21.79% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.40 | +614.29% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $34.42 | +202.15% | 20 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $90 → $22 | $2.97 | +640.74% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.94 | +376.19% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $120.94 | -23.10% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $29.22 | +132.72% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $28.17 | +276.29% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.04 | +197.62% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $17.12 | +227.10% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.48 | +3,557.26% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $25.60 | +122.66% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $3.69 | +496.21% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $3.72 | +356.99% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.85 | +809.09% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $58.56 | -35.11% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $49.15 | +44.46% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $2.48 | +101.61% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $35.07 | +8.35% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $11.22 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.38 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $12.69 | +2,027.66% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $149.89 | - | 2 | Apr 23, 2020 |
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $7.20
Upside: +261.11%
89bio
Sep 19, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $14.79
Upside: -
Astria Therapeutics
Sep 17, 2025
Reiterates: Overweight
Price Target: $49
Current: $12.44
Upside: +293.89%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $32.92
Upside: +91.37%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $38.09
Upside: +285.93%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $70.02
Upside: +17.11%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $7.13
Upside: +40.25%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $22.99
Upside: +21.79%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.40
Upside: +614.29%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $34.42
Upside: +202.15%
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $2.97
Upside: +640.74%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.94
Upside: +376.19%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $120.94
Upside: -23.10%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $29.22
Upside: +132.72%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $28.17
Upside: +276.29%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.04
Upside: +197.62%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $17.12
Upside: +227.10%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.48
Upside: +3,557.26%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $25.60
Upside: +122.66%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $3.69
Upside: +496.21%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $3.72
Upside: +356.99%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.85
Upside: +809.09%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $58.56
Upside: -35.11%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $49.15
Upside: +44.46%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $2.48
Upside: +101.61%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $35.07
Upside: +8.35%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $11.22
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.38
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $12.69
Upside: +2,027.66%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $149.89
Upside: -